Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (1): 84-89.DOI: 10.3969/j.issn.1673-8640.2025.01.015
Previous Articles Next Articles
CHEN Dingzhong, YANG Wen, FENG Yanju, LIANG Xian, ZHANG Xiaozhen
Received:
2024-03-15
Revised:
2024-07-11
Online:
2025-01-30
Published:
2025-02-17
CLC Number:
CHEN Dingzhong, YANG Wen, FENG Yanju, LIANG Xian, ZHANG Xiaozhen. Predictive value of combined determination of serum SFRP5 and KLK1 for myocardial no-reflow after PCI in patients with ST-segment elevation myocardial infarction[J]. Laboratory Medicine, 2025, 40(1): 84-89.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.01.015
组别 | 例数 | SFRP5/(ng·mL-1) | KLK1/(ng·L-1) |
---|---|---|---|
正常对照组 | 156 | 43.83±4.12 | 35.26±3.04 |
STEMI组 | 156 | ||
术前 | 32.71±3.85* | 24.77±2.93* | |
术后 | 33.18±3.97* | 25.34±3.06* |
组别 | 例数 | SFRP5/(ng·mL-1) | KLK1/(ng·L-1) |
---|---|---|---|
正常对照组 | 156 | 43.83±4.12 | 35.26±3.04 |
STEMI组 | 156 | ||
术前 | 32.71±3.85* | 24.77±2.93* | |
术后 | 33.18±3.97* | 25.34±3.06* |
组别 | 例数 | SFRP5/(ng·mL-1) | KLK1/(ng·L-1) |
---|---|---|---|
复流组 | 132 | 33.72±4.07 | 25.68±3.47 |
无复流组 | 24 | 27.16±2.42 | 19.75±2.51 |
t值 | 7.642 | 7.991 | |
P值 | <0.001 | <0.001 |
组别 | 例数 | SFRP5/(ng·mL-1) | KLK1/(ng·L-1) |
---|---|---|---|
复流组 | 132 | 33.72±4.07 | 25.68±3.47 |
无复流组 | 24 | 27.16±2.42 | 19.75±2.51 |
t值 | 7.642 | 7.991 | |
P值 | <0.001 | <0.001 |
组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 基础疾病 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | 高血压/ [例(%)] | 糖尿病/ [例(%)] | 高脂血症/[例(%)] | ||||||||||
复流组 | 132 | 105(79.55) | 27(20.45) | 54.74±7.91 | 24.32±2.56 | 45(34.09) | 33(25.00) | 34(25.76) | ||||||
无复流组 | 24 | 18(75.00) | 6(25.00) | 54.82±7.98 | 24.41±2.71 | 11(45.83) | 7(29.17) | 9(37.50) | ||||||
统计值 | 0.252 | 0.046 | 0.157 | 1.217 | 0.185 | 1.402 | ||||||||
P值 | 0.616 | 0.964 | 0.875 | 0.270 | 0.667 | 0.236 | ||||||||
组别 | 发病至手术 时间/h | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | GRACE评分/分 | Gensini积分/分 | CK-MB/(U·L-1) | cTnI/ (μg·L-1) | |||||||
复流组 | 6.11±0.85 | 42(31.82) | 49(37.12) | 118.56±13.85 | 69.83±13.25 | 172.36±37.15 | 10.75±2.73 | |||||||
无复流组 | 6.13±0.93 | 9(37.50) | 8(33.33) | 127.05±15.17 | 91.47±14.38 | 191.47±41.63 | 12.13±3.15 | |||||||
统计值 | 0.105 | 0.298 | 0.126 | 2.722 | 7.264 | 2.275 | 2.224 | |||||||
P值 | 0.917 | 0.585 | 0.723 | 0.007 | <0.001 | 0.024 | 0.028 | |||||||
组别 | Myo/ (μg·L-1) | BNP/(pg·mL-1) | PLT计数/(×109·L-1) | WBC计数/(×109·L-1) | SCr/(μmol·L-1) | Cys C/(mg·L-1) | Hcy/(μmol·L-1) | DD/ (μg·L-1) | ||||||
复流组 | 186.12±20.14 | 1122.75±214.32 | 214.75±32.56 | 10.42±3.72 | 121.28±31.51 | 4.49±1.26 | 35.32±5.39 | 325.71±50.76 | ||||||
无复流组 | 187.25±20.23 | 1140.53±223.57 | 232.47±33.61 | 10.53±3.75 | 130.15±27.29 | 5.02±1.41 | 37.21±5.28 | 328.43±52.51 | ||||||
统计值 | 0.253 | 0.371 | 2.441 | 0.133 | 1.293 | 1.861 | 1.585 | 0.240 | ||||||
P值 | 0.801 | 0.711 | 0.016 | 0.894 | 0.198 | 0.065 | 0.115 | 0.810 |
组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 基础疾病 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | 高血压/ [例(%)] | 糖尿病/ [例(%)] | 高脂血症/[例(%)] | ||||||||||
复流组 | 132 | 105(79.55) | 27(20.45) | 54.74±7.91 | 24.32±2.56 | 45(34.09) | 33(25.00) | 34(25.76) | ||||||
无复流组 | 24 | 18(75.00) | 6(25.00) | 54.82±7.98 | 24.41±2.71 | 11(45.83) | 7(29.17) | 9(37.50) | ||||||
统计值 | 0.252 | 0.046 | 0.157 | 1.217 | 0.185 | 1.402 | ||||||||
P值 | 0.616 | 0.964 | 0.875 | 0.270 | 0.667 | 0.236 | ||||||||
组别 | 发病至手术 时间/h | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | GRACE评分/分 | Gensini积分/分 | CK-MB/(U·L-1) | cTnI/ (μg·L-1) | |||||||
复流组 | 6.11±0.85 | 42(31.82) | 49(37.12) | 118.56±13.85 | 69.83±13.25 | 172.36±37.15 | 10.75±2.73 | |||||||
无复流组 | 6.13±0.93 | 9(37.50) | 8(33.33) | 127.05±15.17 | 91.47±14.38 | 191.47±41.63 | 12.13±3.15 | |||||||
统计值 | 0.105 | 0.298 | 0.126 | 2.722 | 7.264 | 2.275 | 2.224 | |||||||
P值 | 0.917 | 0.585 | 0.723 | 0.007 | <0.001 | 0.024 | 0.028 | |||||||
组别 | Myo/ (μg·L-1) | BNP/(pg·mL-1) | PLT计数/(×109·L-1) | WBC计数/(×109·L-1) | SCr/(μmol·L-1) | Cys C/(mg·L-1) | Hcy/(μmol·L-1) | DD/ (μg·L-1) | ||||||
复流组 | 186.12±20.14 | 1122.75±214.32 | 214.75±32.56 | 10.42±3.72 | 121.28±31.51 | 4.49±1.26 | 35.32±5.39 | 325.71±50.76 | ||||||
无复流组 | 187.25±20.23 | 1140.53±223.57 | 232.47±33.61 | 10.53±3.75 | 130.15±27.29 | 5.02±1.41 | 37.21±5.28 | 328.43±52.51 | ||||||
统计值 | 0.253 | 0.371 | 2.441 | 0.133 | 1.293 | 1.861 | 1.585 | 0.240 | ||||||
P值 | 0.801 | 0.711 | 0.016 | 0.894 | 0.198 | 0.065 | 0.115 | 0.810 |
项目 | SFRP5 | KLK1 | |||
---|---|---|---|---|---|
r值 | P值 | r值 | P值 | ||
CK-MB | -0.423 | <0.001 | -0.452 | <0.001 | |
cTnI | -0.415 | <0.001 | -0.439 | <0.001 | |
PLT计数 | -0.447 | <0.001 | -0.471 | <0.001 | |
Gensini积分 | -0.483 | <0.001 | -0.495 | <0.001 | |
GRACE评分 | -0.512 | <0.001 | -0.463 | <0.001 |
项目 | SFRP5 | KLK1 | |||
---|---|---|---|---|---|
r值 | P值 | r值 | P值 | ||
CK-MB | -0.423 | <0.001 | -0.452 | <0.001 | |
cTnI | -0.415 | <0.001 | -0.439 | <0.001 | |
PLT计数 | -0.447 | <0.001 | -0.471 | <0.001 | |
Gensini积分 | -0.483 | <0.001 | -0.495 | <0.001 | |
GRACE评分 | -0.512 | <0.001 | -0.463 | <0.001 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
SFRP5 | -0.665 | 0.163 | 16.698 | <0.001 | 0.514(0.374~0.707) |
KLK1 | -0.509 | 0.165 | 9.491 | 0.002 | 0.601(0.435~0.831) |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
SFRP5 | -0.665 | 0.163 | 16.698 | <0.001 | 0.514(0.374~0.707) |
KLK1 | -0.509 | 0.165 | 9.491 | 0.002 | 0.601(0.435~0.831) |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
SFRP5 | 0.881(0.820~0.927) | 30.34 ng·mL-1 | 87.50 | 81.06 | 0.686 |
KLK1 | 0.885(0.824~0.930) | 23.38 ng·L-1 | 91.67 | 80.30 | 0.720 |
联合检测 | 0.949(0.901~0.977) | 0.118 | 95.83 | 80.30 | 0.761 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
SFRP5 | 0.881(0.820~0.927) | 30.34 ng·mL-1 | 87.50 | 81.06 | 0.686 |
KLK1 | 0.885(0.824~0.930) | 23.38 ng·L-1 | 91.67 | 80.30 | 0.720 |
联合检测 | 0.949(0.901~0.977) | 0.118 | 95.83 | 80.30 | 0.761 |
[1] | MITSIS A, GRAGNANO F. Myocardial infarction with and without ST-segment elevation:a contemporary reappraisal of similarities and differences[J]. Curr Cardiol Rev, 2021, 17(4):e230421189013. |
[2] | AKBARI T, AL-LAMEE R. Percutaneous coronary intervention in multi-vessel disease[J]. Cardiovasc Revasc Med, 2022, 44:80-91. |
[3] | DAMLUJI A A, VAN DIEPEN S, KATZ J N, et al. Mechanical complications of acute myocardial infarction:a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(2):e16-e35. |
[4] | HUANG X, YAN Y, ZHENG W, et al. Secreted frizzled-related protein 5 protects against cardiac rupture and improves cardiac function through inhibiting mitochondrial dysfunction[J]. Front Cardiovasc Med, 2021, 8:682409. |
[5] |
DING N, ZHENG C. Secreted frizzled-related protein 5 promotes angiogenesis of human umbilical vein endothelial cells and alleviates myocardial injury in diabetic mice with myocardial infarction by inhibiting Wnt5a/JNK signaling[J]. Bioengineered, 2022, 13(5):11656-11667.
DOI PMID |
[6] | CUI K, LUAN Y, TANG Z, et al. Human tissue kallikrein-1 protects against the development of erectile dysfunction in a rat model of hyperhomocysteinemia[J]. Asian J Androl, 2019, 21(5):508-515. |
[7] | RHALEB N E, YANG X P, CARRETERO O A. The kallikrein-kinin system as a regulator of cardiovascular and renal function[J]. Compr Physiol, 2011, 1(2):971-993. |
[8] | 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会,《中国循环杂志》编辑委员会. 急性心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2001, 29(12):710-725. |
[9] | 周晓丹, 王岩, 项军, 等. 肌钙蛋白、SNYTAX积分、GRACE评分与老年冠心病PCI术后再次血运重建的关系[J]. 疑难病杂志, 2023, 22(8):824-828. |
[10] | 余朝晖, 王东, 金强, 等. 血小板/淋巴细胞比值对急性ST段抬高型心肌梗死患者PCI术后心肌无复流的预测价值[J]. 中国现代医学杂志, 2020, 30(23):27-31. |
[11] | WIVIOTT S D, MORROW D A, FREDERICK P D, et al. Application of the thrombolysis in myocardial infarction risk index in non-ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol, 2006, 47(8):1553-1558. |
[12] |
成景松, 阮家安, 孟建华. 血浆DD联合GRACE评分在老年急性心肌梗死预后评估中的价值[J]. 检验医学, 2022, 37(2):162-164.
DOI |
[13] | HAUSENLOY D J, CHILIAN W, CREA F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury:a target for cardioprotection[J]. Cardiovasc Res, 2019, 115(7):1143-1155. |
[14] | CAIAZZO G, MUSCI R L, FREDIANI L, et al. State of the art:no-reflow phenomenon[J]. Cardiol Clin, 2020, 38(4):563-573. |
[15] | HONG P, WANG L, WANG H, et al. Effect of secreted frizzled-related protein 5 in mice with heart failure[J]. Evid Based Complement Alternat Med, 2022, 2022:1606212. |
[16] |
DU Y, ZHAO Y, ZHU Y, et al. High serum secreted frizzled-related protein 5 levels associates with early improvement of cardiac function following ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention[J]. J Atheroscler Thromb, 2019, 26(10):868-878.
DOI PMID |
[17] | KONOPLYANNIKOV M, HAIDER K H, LAI V K, et al. Activation of diverse signaling pathways by ex-vivo delivery of multiple cytokines for myocardial repair[J]. Stem Cells Dev, 2013, 22(2):204-215. |
[18] | 张秀金, 王建军, 张海燕, 等. 血清MCP-1、SFRP5水平与急性ST段抬高型心肌梗死患者心功能及预后的关系研究[J]. 国际检验医学杂志, 2021, 42(19):2351-2355. |
[19] | HUANG S, CHEN M, YU H, et al. Co-expression of tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 improves myocardial ischemia-reperfusion injury by promoting angiogenesis and inhibiting oxidative stress[J]. Mol Med Rep, 2021, 23(2):166. |
[20] | 殷雪娇, 李慧, 梁荣珍, 等. 血清sTWEAK、KLK1水平预测老年急性非ST段抬高型心肌梗死病人急诊PCI预后的研究[J]. 实用老年医学, 2022, 36(4):364-368. |
[21] | 吴永茂, 李泽荣, 朱深政. 血清KLK1、RBP4及SYNTAX-11评分预测血运重建后STEMI患者预后的临床价值[J]. 中国急救复苏与灾害医学杂志, 2022, 17(2):217-220. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||